Compare Hershey Co (HSY) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hershey Co vs BIO-TECHNE Corp — how do they compare? Hershey Co trades at $162.5 (market cap $32.66B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: Hershey Co is far larger — about 2.9× BIO-TECHNE Corp's market cap, and Hershey Co pays the higher dividend (3.57%). Which is the better fit depends on your goals — on Pluang, investors hold Hershey Co for 135 Days and BIO-TECHNE Corp for 63 Days on average.
| HSY | TECH | |
|---|---|---|
Market Cap | $32.66B | $11.36B |
Volume | 1,578,237 | 5,390,331 |
Sector | Consumer Staples | Health |
52-Week High | $236.28 | $72.61 |
52-Week Low | $157.61 | $43.31 |
Typical Hold Time | 135 Days | 63 Days |
Enterprise Value | $37.79B | $11.39B |
Dividend Yield | 3.57% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hershey (HSY) trades at $160.34, down 0.29% on the day, with a bearish technical signal from moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Strong profitability metrics include a 32.81% ROE and 12.24% net margin, though 2025 net income declined significantly from 2024 levels. Recent corporate developments include new international leadership and ongoing brand investment initiatives.
The stock presents a mixed outlook with 26% upside to the consensus price target of $204.62, but faces headwinds from cocoa cost pressures and technical weakness. While dividend growth has resumed after a nearly two-year freeze, investors should weigh strong brand positioning against commodity volatility and declining institutional holdings in recent quarters.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
